Bryan Johnson, Psilocybin, and the Biohacker Crossover

In November 2025, Bryan Johnson — the biohacker best known for spending two million dollars a year trying not to die — ran what he called the most quantified psychedelic experiment in history on himself. Two structured doses of Psilocybe cubensis, three weeks apart. The first on November 9, containing a lab-confirmed 24.98 mg of psilocybin. The second on November 30, containing 28 mg. In between and around those doses, Johnson and his Blueprint team tracked 249 biomarkers — blood, urine, stool, saliva, fertility panels, multi-omics profiling, brain scans — and published the results on the Blueprint website under the headline “I Took Shrooms for Science.” A month later, on December 1, he took a much larger dose (5.24 grams of dried mushrooms, 28 mg of psilocybin) and livestreamed the six-hour experience to nearly a million viewers on X, with Marc Benioff, Naval Ravikant, and David Friedberg as on-screen guests and Grimes providing a live DJ set. In March 2026 he did it again with 5-MeO-DMT, this time for roughly 700,000 live viewers.

Whatever you think of the man, the act was consequential. Johnson has a readership of millions of people who are, statistically, among the most cautious, most data-driven, most optimization-obsessed self-experimenters on the planet. The biohacker community has historically treated psychedelics with the same skepticism it treats anything that cannot be A/B tested with clean controls — which is to say, politely, from a distance. Johnson’s publication changed the temperature of that conversation.

What the data actually showed

The headline biomarker story is strikingly positive. Across the 249 markers the Blueprint team tracked before and after the two-dose protocol, the shifts were consistent and in the direction a longevity researcher would celebrate:

Brain and cognition readouts showed increased plasticity indicators and desynchronized default-network activity during the acute experience, alongside self-reported increases in creativity, playfulness, openness, and reduced mental rigidity.

Johnson’s own summary from his X post was blunt:

"I think magic mushrooms are a longevity therapy. After seeing the data from two doses, psilocybin offers unique longevity effects that complement the best performing therapies I've done to date." Bryan Johnson, via X, Nov 2025

If you are in the habit of reading psychedelic research credulously, none of this is surprising. If you are in the habit of reading it skeptically, the interesting thing is that almost all the signals — stress markers, glucose, inflammation, network connectivity — are moving in directions that would be celebrated coming out of any other longevity intervention. That was not the expected result. The skeptical prior for psilocybin-as-longevity-intervention was that the acute physiological stress of a psychedelic experience should, if anything, briefly disrupt the kind of biomarkers Johnson measures. It didn’t. It improved them.

Whether those improvements are durable, whether they replicate in anyone else’s body, and whether they can be attributed to the psilocybin rather than to the extraordinary surrounding protocol (sleep, diet, training, the whole Blueprint stack) is the unresolved question. N equals one, in his own context, with his own stack as confounders. A promising single-subject result is not a generalizable finding. Johnson himself is clear about this in the Blueprint writeup.

Why the biohacker community is paying attention

There is a specific audience for whom Johnson’s data is a permission slip. Call them the Farming Nodes — the quantified-self people, the engineers, the founders, the endurance athletes, the biohackers, the people who do not take anything seriously until they can see it on a chart. Historically, this audience has held psychedelics at arm’s length. The research was inconclusive. The stories were too soft. The brands were too woo. The cost-benefit was unclear.

Johnson is one of their own. When he publishes his psilocybin protocol on the same blog where he publishes his rapamycin data, his fasting data, and his daily protocols, the community reads it with the same level of attention it reads those pieces. And the signal the community is receiving from him is: this is worth taking seriously, this is worth measuring carefully, this is not a party drug, this is a real intervention that a serious person can incorporate into a serious program.

Five years ago, a microdose was mostly something you heard about from a yoga teacher or a creative director. Today it is something you hear about from a sleep scientist or a longevity investor. The conversation has migrated across personality types, and Johnson is one of the people doing the migrating on stage.

The livestream question

The December 1 psilocybin livestream and the March 2026 5-MeO-DMT livestream are a separate conversation from the biomarker experiment, and they deserve to be named separately. The Blueprint experiment was a careful, quantified, blood-draw-heavy investigation at two measured doses. The livestreams were macro-dose spectacles with celebrity guests and a DJ.

Reasonable people are going to disagree about whether livestreaming a psychedelic experience to a million viewers is the most useful contribution a longevity researcher could make to the field. Some of that disagreement is aesthetic. Some of it is substantive — the harm-reduction community flagged the livestreams as giving a mixed message about how to approach these medicines, with concerns about the production-event framing overshadowing the careful preparation-and-integration posture serious practitioners emphasize. The Ecstatic Integration newsletter, among others, wrote a measured critique of the livestream format.

The Movement’s position is that the biomarker experiment and the spectacle livestream are different artifacts of the same phenomenon and should be evaluated separately. The data drop is the thing worth taking seriously in a research sense. The livestream is a cultural event — not nothing, but a different kind of thing — and the two should not be conflated.

Where the caution lives

None of this is a full endorsement. Bryan Johnson is an extreme case. The baseline data he works from is unlike anyone else’s baseline data. The resources he brings to an experiment are unlike anyone else’s resources. The measurement stack he runs is not something the average person can reproduce. What works in a Blueprint-funded self-experiment may not translate cleanly to the person trying this with a home kit and a journal.

There is also the question, which the Movement keeps coming back to, of what you are optimizing for. Johnson’s public project is longevity — living as long as possible in as good a body as possible. Psilocybin as a tool in that project is a specific use. What a lot of the people reading about this practice are actually seeking is not a longer life but a fuller one: less anxiety, more creativity, more presence with the people they love, more willingness to do the things they already know how to do but have stopped doing. The Blueprint frame does not capture that. And a microdose protocol run by a person whose goal is “feel more alive this week” is a different protocol than one run by a person whose goal is “measure every variable until death recedes.”

Both are legitimate. They are not the same.

What the Movement thinks

We are not the biohacker site. We are not running our own clinical trial. But we notice, with interest, that a person whose entire public identity is built around rigorous self-measurement has taken this medicine seriously enough to run a full biomarker panel on himself and publish the results in public. That is not a small thing. It is the kind of thing that, in retrospect, people will point to as the moment the conversation crossed a line.

Our take is the same one we hold for all the archetypes: the medicine is real, the practice is serious, the work is yours, and the version of you on the other side of the practice is the one who gets to decide whether what you are optimizing for is actually the thing worth optimizing for. The spreadsheet is a tool. It is not the answer. The answer is whatever the medicine, the practice, and the people you love are telling you when you are quiet enough to hear.

Sources

• Blueprint (Bryan Johnson). “I Took Shrooms for Science” and “Magic Mushroom Biomarker Results.” blueprint.bryanjohnson.com/blogs/news/magic-mushrooms · magic-mushroom-biomarker-results
• Johnson, B. (2025). X post on psilocybin longevity conclusions. x.com/bryan_johnson
• TechCrunch, “The spectacle of Bryan Johnson and his livestreamed shrooms trip” (December 2, 2025). techcrunch.com
• SF Standard, “Longevity expert Bryan Johnson takes magic mushrooms on a six-hour livestream” (December 1, 2025). sfstandard.com
• Rolling Stone, “Could a Psychedelic Stop Your Brain From Aging? Longevity Guru Bryan Johnson Is Giving It a Shot” (March 2026). rollingstone.com
• Ecstatic Integration, “Bryan Johnson’s live-streamed mushroom trip” (a critical harm-reduction read). ecstaticintegration.org

---

The Microdose Movement is an educational community, not a medical provider. Nothing in this article is medical advice. We are not affiliated with, endorsed by, or in communication with Bryan Johnson or the Blueprint project. This is editorial commentary based on publicly released data and coverage.